thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » COVAXIN booster can defend new variants of concern: ICMR Study

COVID Vaccines

COVAXIN booster can defend new variants of concern: ICMR Study

TheNewsFacts
Last updated: June 15, 2022 8:34 pm
TheNewsFacts
Share
Covaxin booster can defend new variants of concern: ICMR Study
SHARE

A COVAXIN booster dose has protective efficacy against the Delta variant and the Omicron sub-variants BA.1.1 and BA.2, according to a recent published study by the Indian Council of Medical Research (ICMR), the National Institute of Virology (NIV), and Bharat Biotech.

Contents
The ICMR-NIV study was published as a pre-print in bioRxivCovaxin Booster: Vaccine Booster have shown to improve the efficacy of many Covid-19 Vaccines in Clinical Trials

The neutralising antibody response against variants of concern, such as Delta and Omicron, was found to be enhanced by the booster dosage of Covaxin. This is a promising study, according to Dr Samiran Panda, additional director-general of the ICMR.

The findings are based on a study conducted on animals and it will be followed up in humans as well. The study was conducted earlier but it took time to get published as per the protocol, Dr Panda said.

The ICMR-NIV study was published as a pre-print in bioRxiv

The ICMR-NIV study was published as a pre-print in bioRxiv on Tuesday under the title “Protective efficacy of Covaxin against Delta and Omicron variants in the hamster model.”

Researchers from the NIV and Bharat Biotech analysed the protective efficacy of COVAXIN following second- and third-dose immunisations against the Delta variant, and studied the efficacy of the same vaccine against Omicron variants in a Syrian hamster model.

The antibody response, clinical observations, viral load reduction and lung disease severity after the virus challenge were studied. Protective responses in terms of the reduction in the lung viral load and lung lesions were observed in both the second and third doses in a Covaxin-immunised group compared to a placebo group following the Delta variant challenge, the study’s authors have said in the report.

In the Delta infection study, researchers compared the protective responses between the second- and third-dose regimens and said they could observe the advantage of the booster dose vaccination. Although the neutralising antibody levels were comparable among the groups, lung disease severity was found more reduced after the third dose.

In the second study, in which the protective response was assessed against Omicron sub-variants BA.1 and BA.2 after three doses of vaccination, the test cases reported less virus shedding, a low lung viral load and lung disease severity.

The immunity generated by the natural infection or vaccination tends to wane with time, and according to the study authors, newly evolving variants also pose challenges to acquired immunity with their immune-escape properties. This underlines the importance of constant monitoring of the virus’s genomic changes and the properties of the evolving variants, the researchers have said.

Covaxin Booster: Vaccine Booster have shown to improve the efficacy of many Covid-19 Vaccines in Clinical Trials

Booster doses have shown to improve the efficacy of many Covid-19 vaccines in clinical trials and have been authorised by many countries.

COVAXIN is an inactivated, whole-virion vaccine licensed in India and 13 other countries. It has shown immunogenicity and protective efficacy against the coronavirus’s B.1 variant possessing the D614G mutation in laboratory animal studies. With the emergence of coronavirus variants, multiple in-vitro studies were conducted to understand the neutralisation potential of the Covaxin-induced immune responses.

The neutralisation potential has been demonstrated with the Alpha, Kappa, Beta, Delta and Omicron variants of the virus. But the neutralising antibody titres against the variants of concern were found reduced in comparison to the ancestral B.1 variant. Among these variants, Omicron was least effectively neutralised in the in-vitro assay. According to the study findings, researchers have said that Covaxin will enhance vaccine effectiveness against Delta-variant infection and protect against Omicron variants BA.1.1 and BA.2.

Note: The aforementioned article is for informational purposes only and is not meant to be a substitute for qualified medical guidance. For any concerns you might have about your health or a medical issue, always seek the advice of your doctor or another certified health expert.

TAGGED: Booster Dose, Covaxin, covaxin booster, Covaxin Booster Dose, covaxin fights variants of concern
Share This Article
Twitter Email Copy Link Print
Previous Article Netflix New Squid Game: The Challenge to be the Biggest Reality Show Netflix New Squid Game: The Challenge to be the Biggest Reality Show
Next Article Here Is The Easiest Way To Check India Post GDS Result 2022 Online 4 Steps to check India Post GDS Result 2022 Online

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

Sonu Sood Says Truth Will Prevail after IT Raids

Sonu Sood has responded to the Income Tax raids at his properties in Mumbai, Lucknow,…

By TheNewsFacts

Apple iPhone 11 Will be History Soon, Price Cuts Likely

Worlds Favorite iPhone 11 will be history soon, as Apple readies its plans to introduce…

By TheNewsFacts

‘Road to IPBL’ India: Sabari Jaishankar vs. Sergio Pettis Face-Off in March

February 4, 2025: Former UFC Lightweight Champion Anthony Pettis is bringing the heat to India…

By TheNewsFacts

You Might Also Like

Dr. Krishna Ella Receives Johns Hopkins Highest Medal of Honor
Latest News

COVAXIN Creator Dr. Krishna Ella Wins Prestigious Johns Hopkins Award

By TheNewsFacts
COVAXIN
Trending News

Covaxin: Facts vs. Fiction – Separating Truth from Misinformation

By TheNewsFacts
Covaxin BHU Study
COVID VaccinesLatest News

Covaxin BHU Study: BB Points Flaws in Data Points, Backs Strong Safety Track Record

By NewsFacts Bureau
COVAXIN safety First
Latest News

COVAXIN Safety Assured: Bharat Biotech Puts Safety First

By TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?